Phillip Frost - Opko Health Chairman of the Board, CEO
| OPK Stock | USD 1.64 0.02 1.20% |
Chairman
Dr. Phillip Frost serves as Chairman of the Board and Chief Executive Officer at Opko health, Inc. Dr. Frost was the Chief Executive Officer of the Company and Chairman of the Board since March 2007. Dr. Frost serves as a director for Castle Brands, a developer and marketer of premium brand spirits, and Cocrystal Pharma, Inc., a publicly traded biotechnology company developing new treatments for viral diseases. He serves as a member of the Board of Trustees of the University of Miami, the Skolkovo Foundation Scientific Advisory Council in Russia, the Shanghai Institute for Advanced Immunochemical Studies in China, and The Florida Council of 100 and as a Trustee of each of the Miami Jewish Home for the Aged and the Mount Sinai Medical Center. He serves as Chairman of Temple EmanuEl, Governor of Tel Aviv University and is a member of the Executive Committee of The Phillip and Patricia Frost Museum of Science. Dr. Frost served as a director of Ladenburg Thalmann Financial Services Inc., an investment banking, asset management, and securities brokerage firm providing services through its principal operating subsidiary, Ladenburg Thalmann Co. Inc., from 2004 to 2018 and had served as its Chairman from July 2006 until September 2018, a director of Teva Pharmaceutical Industries, Limited, or Teva from January 2006 until February 2015 and had served as Chairman of the Board of Teva from March 2010 until December 2014. Dr. Frost previously served as Vice Chairman of Cogint, Inc., now known as Fluent, Inc., and as a director for Sevion Therapeutics, Inc. prior to its merger with Eloxx Pharmaceuticals, Inc., and TransEnterix, Inc., . Dr. Frost had served as Chairman of the Board of Directors and Chief Executive Officer of IVAX Corporation from 1987 until its acquisition by Teva in January 2006. Dr. Frost was Chairman of the Board of Directors of Key Pharmaceuticals, Inc. since 2007.
| Age | 89 |
| Tenure | 18 years |
| Address | 4400 Biscayne Boulevard, Miami, FL, United States, 33137 |
| Phone | 305 575 4100 |
| Web | https://www.opko.com |
Phillip Frost Latest Insider Activity
Tracking and analyzing the buying and selling activities of Phillip Frost against Opko Health stock is an integral part of due diligence when investing in Opko Health. Phillip Frost insider activity provides valuable insight into whether Opko Health is net buyers or sellers over its current business cycle. Note, Opko Health insiders must abide by specific rules, including filing SEC forms every time they buy or sell Opko Health'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Phillip Frost over two weeks ago Acquisition by Phillip Frost of 47537 shares of Opko Health at 1.4738 subject to Rule 16b-3 | ||
Phillip Frost over three weeks ago Acquisition by Phillip Frost of 150000 shares of Opko Health at 1.4695 subject to Rule 16b-3 | ||
Phillip Frost over a month ago Acquisition by Phillip Frost of 500000 shares of Opko Health at 1.4817 subject to Rule 16b-3 | ||
Phillip Frost over a month ago Acquisition by Phillip Frost of 100000 shares of Opko Health at 1.6198 subject to Rule 16b-3 |
Opko Health Management Efficiency
The company has Return on Asset of (0.0897) % which means that on every $100 spent on assets, it lost $0.0897. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.0939) %, meaning that it generated no profit with money invested by stockholders. Opko Health's management efficiency ratios could be used to measure how well Opko Health manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.37. The value of Return On Capital Employed is expected to slide to -0.08. At this time, Opko Health's Total Current Liabilities is quite stable compared to the past year. Liabilities And Stockholders Equity is expected to rise to about 2.4 B this year, although the value of Non Current Liabilities Other will most likely fall to about 10.4 M.Similar Executives
| Found 3 records | CHAIRMAN Age | ||
| Ming Hsieh | Fulgent Genetics | 69 | |
| Matthew Rabinowitz | Natera Inc | 52 | |
| Boon Koh | Agilent Technologies | 70 | |
Management Performance
| Return On Equity | -0.0939 | ||||
| Return On Asset | -0.0897 |
Opko Health Leadership Team
Elected by the shareholders, the Opko Health's board of directors comprises two types of representatives: Opko Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Opko. The board's role is to monitor Opko Health's management team and ensure that shareholders' interests are well served. Opko Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Opko Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Arie Gutman, Pres API | ||
| Dr MBA, Vice Officer | ||
| FACP FASN, Senior Renal | ||
| Adam Logal, CFO, Chief Accounting Officer, Sr. VP and Treasurer | ||
| David Okrongly, President Diagnostics | ||
| Antonio Cruz, President Therapeutics | ||
| Elias MD, President Chairman | ||
| JD Esq, Chief Laboratories | ||
| Charles Bishop, Chief Renal | ||
| Hans Berner, President Iberoamerica | ||
| James DeMarco, VP Sales | ||
| Giovanni MD, Chief Officer | ||
| Phillip Frost, Chairman of the Board, CEO | ||
| Akhtar Ashfaq, Senior Vice President - Clinical Research and Development of OPKO Health's Renal Division | ||
| MBA MBA, Vice Officer | ||
| Jon MD, Advisor |
Opko Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Opko Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0939 | ||||
| Return On Asset | -0.0897 | ||||
| Profit Margin | (0.19) % | ||||
| Operating Margin | (0.62) % | ||||
| Current Valuation | 1.21 B | ||||
| Shares Outstanding | 672.8 M | ||||
| Shares Owned By Insiders | 54.52 % | ||||
| Shares Owned By Institutions | 29.22 % | ||||
| Number Of Shares Shorted | 88.64 M | ||||
| Price To Earning | 7.46 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Opko Health. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more information on how to buy Opko Stock please use our How to buy in Opko Stock guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Opko Health. If investors know Opko will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Opko Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.191 | Earnings Share (0.19) | Revenue Per Share | Quarterly Revenue Growth (0.03) | Return On Assets |
The market value of Opko Health is measured differently than its book value, which is the value of Opko that is recorded on the company's balance sheet. Investors also form their own opinion of Opko Health's value that differs from its market value or its book value, called intrinsic value, which is Opko Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Opko Health's market value can be influenced by many factors that don't directly affect Opko Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Opko Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if Opko Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Opko Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.